Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

The hypothalamus of an adult living with narcolepsy type 1 (NT1) measures smaller than that of a person without the disorder, ...

The federal government's posture in Texas v Kennedy —a lawsuit over HHS's 2024 update to Section 504 of the Rehabilitation ...

A large, long-term real-world study found that biologic therapy for psoriasis is linked to a significantly lower risk of ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

Increasing travel burden was associated with lower surgery likelihood, with a 6% odds reduction per additional travel hour ...

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. In its article, The ...